Clinical Trial Update: Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating immunogenicity and safety of two two-dose HPV vaccine schedules in girls aged 9-14; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer Prevention
• Human Papillomavirus Infection
• Papillomavirus Infections

Drugs mentioned

• HPV vaccine

Snippet

Sponsor: GlaxoSmithKline | Conditions: Infections, Papillomavirus | Phase 3 | Status: COMPLETED | Results posted: 2013-12-05